Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
67High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06769425CT.gov HS-10502 Combination Treatment in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06889688CT.gov Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT07371910CT.gov Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT06339281CT.gov A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06447623CT.gov Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer | — | Recruiting | — | — | — |
NCT05759572CT.gov Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT05594095CT.gov SNF Platform Study of HR+/ HER2-advanced Breast Cancer | — | Recruiting | — | — | — |
NCT05556200CT.gov A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs | — | Unknown | — | — | — |
NCT05582499CT.gov Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | — | Recruiting | — | — | — |
NCT04803539CT.gov A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC | — | Recruiting | — | — | — |
Show 15 more trialsShow fewer
NCT04722718CT.gov Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer | — | Unknown | — | — | — |
NCT04335006CT.gov A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer. | — | Terminated | — | — | — |
NCT04355858CT.gov Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer | — | Unknown | — | — | — |
NCT04303741CT.gov A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC | — | Unknown | — | — | — |
NCT03735082CT.gov Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer | — | Unknown | — | — | — |
NCT03982485CT.gov Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03457467CT.gov Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer | — | Unknown | — | — | — |
NCT03394287CT.gov A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC | — | Completed | — | — | — |
NCT03580395CT.gov Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer | — | Unknown | — | — | — |
NCT03535961CT.gov Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer | — | Completed | — | — | — |
NCT03086785CT.gov Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer | — | Unknown | — | — | — |
NCT03384511CT.gov The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. | — | Completed | — | — | — |
NCT02768415CT.gov Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer | — | Unknown | — | — | — |
NCT02878057CT.gov Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006) | — | Completed | — | — | — |
NCT01176669CT.gov Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rivoceranib (this asset) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Approved | BB · 64 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Rivoceranib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastric Cancer | — | P4 | BBB · 73 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BBB · 72 |
| Cancer | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rivoceranib in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rivoceranib-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →